CA
CORT icon

Continuum Advisory’s Corcept Therapeutics CORT Stock Holding History

Continuum Advisory’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435 Buy
+5
New +$302 ﹤0.01% 1912
2024
Q4 		– Sell
-15
Closed -$822 – 1879
2024
Q3 		$822 Buy
+15
New +$533 ﹤0.01% 1671

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Continuum Advisory's CORT Position: Q2 2026 in Review

Continuum Advisory opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 5 shares worth $435. The stake represents ﹤0.01% of the portfolio and ranks #1912 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in CORT as recently as Q3 2024.

Continuum Advisory first reported a position in CORT in Q3 2024 and has held it in 2 quarters since. The position peaked at $822 in Q3 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Continuum Advisory held 5 shares of Corcept Therapeutics worth $435 as of Q2 2026.
  • Corcept Therapeutics was a new Continuum Advisory position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1912 holding.
  • Continuum Advisory first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Continuum Advisory's Corcept Therapeutics position peaked at $822 in Q3 2024.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.